Shannon E Conneely1, Alexandra M Stevens2. 1. Department of Pediatric Hematology/Oncology, Baylor College of Medicine/Texas Children's Hospital, 6701 Fannin, Suite 1510, Houston, TX, 77030, USA. seconnee@texaschildrens.org. 2. Department of Pediatric Hematology/Oncology, Baylor College of Medicine/Texas Children's Hospital, 6701 Fannin, Suite 1510, Houston, TX, 77030, USA.
Abstract
PURPOSE OF REVIEW: Acute myeloid leukemia (AML) in children remains a challenging disease to cure with suboptimal outcomes particularly when compared to the more common lymphoid leukemias. Recent advances in the genetic characterization of AML have enhanced understanding of individualized patient risk, which has also led to the development of new therapeutic strategies. Here, we review key cytogenetic and molecular features of pediatric AML and how new therapies are being used to improve outcomes. RECENT FINDINGS: Recent studies have revealed an increasing number of mutations, including WT1, CBFA2T3-GLIS2, and KAT6A fusions, DEK-NUP214 and NUP98 fusions, and specific KMT2A rearrangements, which are associated with poor outcomes. However, outcomes are starting to improve with the addition of therapies such as gemtuzumab ozogamicin and FLT3 inhibitors, initially developed in adult AML. The combination of advanced risk stratification and ongoing improvements and innovations in treatment strategy will undoubtedly lead to better outcomes for children with AML.
PURPOSE OF REVIEW: Acute myeloid leukemia (AML) in children remains a challenging disease to cure with suboptimal outcomes particularly when compared to the more common lymphoid leukemias. Recent advances in the genetic characterization of AML have enhanced understanding of individualized patient risk, which has also led to the development of new therapeutic strategies. Here, we review key cytogenetic and molecular features of pediatric AML and how new therapies are being used to improve outcomes. RECENT FINDINGS: Recent studies have revealed an increasing number of mutations, including WT1, CBFA2T3-GLIS2, and KAT6A fusions, DEK-NUP214 and NUP98 fusions, and specific KMT2A rearrangements, which are associated with poor outcomes. However, outcomes are starting to improve with the addition of therapies such as gemtuzumab ozogamicin and FLT3 inhibitors, initially developed in adult AML. The combination of advanced risk stratification and ongoing improvements and innovations in treatment strategy will undoubtedly lead to better outcomes for children with AML.
Authors: Lawrence D Mayer; Troy O Harasym; Paul G Tardi; Natashia L Harasym; Clifford R Shew; Sharon A Johnstone; Euan C Ramsay; Marcel B Bally; Andrew S Janoff Journal: Mol Cancer Ther Date: 2006-07 Impact factor: 6.261
Authors: Johannes Raedler; Sita Heyde; Marie Kolokythas; Anna Eichinger; Vera Binder; Irene Schmid; Christoph Klein; Tobias Feuchtinger; Michael H Albert Journal: Br J Haematol Date: 2020-04-28 Impact factor: 6.998
Authors: Alan S Gamis; Todd A Alonzo; Soheil Meshinchi; Lillian Sung; Robert B Gerbing; Susana C Raimondi; Betsy A Hirsch; Samir B Kahwash; Amy Heerema-McKenney; Laura Winter; Kathleen Glick; Stella M Davies; Patti Byron; Franklin O Smith; Richard Aplenc Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: I H I M Hollink; C M Zwaan; M Zimmermann; T C J M Arentsen-Peters; R Pieters; J Cloos; G J L Kaspers; S S N de Graaf; J Harbott; U Creutzig; D Reinhardt; M M van den Heuvel-Eibrink; C Thiede Journal: Leukemia Date: 2008-11-20 Impact factor: 11.528
Authors: Alexander E Perl; Jessica K Altman; Jorge Cortes; Catherine Smith; Mark Litzow; Maria R Baer; David Claxton; Harry P Erba; Stan Gill; Stuart Goldberg; Joseph G Jurcic; Richard A Larson; Chaofeng Liu; Ellen Ritchie; Gary Schiller; Alexander I Spira; Stephen A Strickland; Raoul Tibes; Celalettin Ustun; Eunice S Wang; Robert Stuart; Christoph Röllig; Andreas Neubauer; Giovanni Martinelli; Erkut Bahceci; Mark Levis Journal: Lancet Oncol Date: 2017-06-20 Impact factor: 41.316
Authors: Roya Rafiee; Lata Chauhan; Todd A Alonzo; Yi-Cheng Wang; Ahlam Elmasry; Michael R Loken; Jessica Pollard; Richard Aplenc; Susana Raimondi; Betsy A Hirsch; Irwin D Bernstein; Alan S Gamis; Soheil Meshinchi; Jatinder K Lamba Journal: Blood Cancer J Date: 2019-05-21 Impact factor: 11.037
Authors: Jan Philipp Bewersdorf; Smith Giri; Rong Wang; Robert T Williams; Martin S Tallman; Amer M Zeidan; Maximilian Stahl Journal: Haematologica Date: 2020-11-01 Impact factor: 9.941
Authors: W Blum; B L Sanford; R Klisovic; D J DeAngelo; G Uy; B L Powell; W Stock; M R Baer; J E Kolitz; E S Wang; E Hoke; K Mrózek; J Kohlschmidt; C D Bloomfield; S Geyer; G Marcucci; R M Stone; R A Larson Journal: Leukemia Date: 2016-09-13 Impact factor: 11.528
Authors: Fabiana Cacace; Rossella Iula; Danilo De Novellis; Valeria Caprioli; Maria Rosaria D'Amico; Giuseppina De Simone; Rosanna Cuccurullo; William G Wierda; Kris Michael Mahadeo; Giuseppe Menna; Francesco Paolo Tambaro Journal: Biomedicines Date: 2022-06-14
Authors: Hiroto Inaba; Jolieke G van Oosterwijk; John C Panetta; Lie Li; Daelynn R Buelow; James S Blachly; Sheila Shurtleff; Ching-Hon Pui; Raul C Ribeiro; Jeffrey E Rubnitz; Stanley Pounds; Sharyn D Baker Journal: Clin Cancer Res Date: 2022-06-13 Impact factor: 13.801
Authors: Jaclyn Rosenzweig; Pallavi M Pillai; Susan Prockop; Ryma Benayed; Lisa Eidenschink Brodersen; Vesna Najfeld; Michael R Loken; Yanming Zhang; Neerav Shukla Journal: Cold Spring Harb Mol Case Stud Date: 2022-04-28
Authors: Clara Vicente-Garcés; Elena Esperanza-Cebollada; Sara Montesdeoca; Montserrat Torrebadell; Susana Rives; José Luis Dapena; Albert Català; Nuria Conde; Mireia Camós; Nerea Vega-García Journal: Front Mol Biosci Date: 2022-04-07